<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362748">
  <stage>Registered</stage>
  <submitdate>13/07/2012</submitdate>
  <approvaldate>20/07/2012</approvaldate>
  <actrnumber>ACTRN12612000772842</actrnumber>
  <trial_identification>
    <studytitle>Phase II pre-operative study of super-castration with combination Degarelix, Abiraterone, Bicalutamide and Prednisone in high-risk localized prostate cancer.</studytitle>
    <scientifictitle>Phase II neo-adjuvant study of super-castration with combination Degarelix, Abiraterone, Bicalutamide and Prednisone in high-risk localized prostate cancer to assess effects on complete pathological response rates.</scientifictitle>
    <utrn>U1111-1132-5860</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an open label phase II trial in the neo-adjuvant setting. After signing informed consent, patients will be treated with supercastration triple therapy (degarelix 240/80 mg subcutaneously once a month, bicalutamide 50 mg orally once a day, abiraterone 1000 mg orally once a day, prednisone 5 mg orally once a day) for a period of 6 months prior to radical prostatectomy.</interventions>
    <comparator>Reported response rate of patients enrolled in neo-adjuvant androgen deprivation trials using older combinations (Gleave et al. 'Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects' which assessed complete response rates in men treated with 3 or 8 months of combination leuprolide 7.5 mg by intramuscular injection once a month and flutamide 250 mg three times a day orally prior to prostatectomy between August 1995 and April 1998).</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of combined androgen deprivation therapy in the neo-adjuvant setting. This will be assessed by patient history and physical examination (height, weight, vital signs), and regular blood tests (full blood count, urea, creatinine and electrolytes, and liver function tests) as well as evaluation of performance status (ECOG)</outcome>
      <timepoint>Every 2 weeks for the first 16 weeks, then every 4 weeks until surgery.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>pT0 response rate on histopathological assessment of the radical prostatectomy specimen.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of organ confined disease on histopathological assessment of the radical prostatectomy specimen.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of specimen confined disease on histopathological assessment of the radical prostatectomy specimen.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlative molecular studies.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically confirmed prostate cancer, present in at least 2 biopsy cores, associated with one of the following features: PSA &gt;20 ng/ml, predominant cancer Gleason pattern 4 or above (Gleason 4+3=7, 8-10), clinical stage &gt;/= T2c.
ECOG 0-1
Otherwise suitable for radical prostatectomy with curative intent.
Normal organ and marrow function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Metastatic disease.
Previous systemic therapy for prostate cancer.
Previous local therapy for prostate cancer (radiotherapy, HIFU, cryotherapy)
History of liver disease or baseline bilirubin &gt;/= 1.5 X ULN or Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt;/=2.5 X ULN
Uncontrolled hypertension
Clinically significant cardiac disease
History of pituitary or adrenal dysfunction 
Hypogonadism or severe androgen deficiency as defined by serum testosterone less than 100 ng/dL</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate>18/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/03/2014</actualenddate>
    <samplesize>17</samplesize>
    <actualsamplesize>17</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Niall Corcoran</primarysponsorname>
    <primarysponsoraddress>Australian Prostate Cancer Research Centre@Epworth
Level 2, 185 Hoddle St,
Richmond, VIC 3121 &amp;
Department of Urology, Royal Melbourne Hospital,
Grattan St., Parkville, VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Epworth Hospital</sponsorname>
      <sponsoraddress>89 Bridge Road
Richmond Vic 3121</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Phil Parente</othercollaboratorname>
      <othercollaboratoraddress>Epworth Eastern Hospital
1 Arnold St,
Box Hill, VIC 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Tony Costello</othercollaboratorname>
      <othercollaboratoraddress>Suite 8.6, The Epworth Centre 
32 Erin Street, Richmond, VIC 3121</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mr. Paul Ruljancich</othercollaboratorname>
      <othercollaboratoraddress>Suite 6, 30 Arnold ST
Box Hill, VIC, 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mr. Jeremy Grummet</othercollaboratorname>
      <othercollaboratoraddress>Ground Floor 322 Glenferrie Road, 
Malvern VIC 3144 &amp;
The Alfred Hospital, 
Commercial Road,
Melbourne. Vic. 3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to evaluate the safety and efficacy of combination Degarelix, Abiraterone, Bicalutamide and Prednisolone in high-risk localised prostate cancer patients. 

Who is it for? 
You may be eligible to join this study if you are aged 18 years or above and have confirmed prostate cancer which is suitable for radical prostatectomy with curative intent. Trial details All participants in this trial will be treated with 'super castration' triple therapy. This involves taking the medications Degarelix, Bicalutamide, Abiraterone and Prednisone for a period of 6 months prior to radical prostatectomy. 

Participants will be assessed at regular intervals in order to determine the safety, tolerability and response rate to treatment when compared with historically treated patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Epworth Human Research Ethics Committee</ethicname>
      <ethicaddress>Epworth Hospital Richmond,
89 Bridge Road
Richmond Vic 3121</ethicaddress>
      <ethicapprovaldate>23/05/2012</ethicapprovaldate>
      <hrec>55512</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr. Niall Corcoran</name>
      <address>Australian Prostate Cancer Research Centre Epworth
Level 2, 185 Hoddle St,
Richmond, VIC 3121, Australia</address>
      <phone>+61 3 9936 8032</phone>
      <fax>+61 3 9429 4683</fax>
      <email>niall.corcoran@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ms Pat Bugeja</name>
      <address>Australian Prostate Cancer Research Centre Epworth
Level 2, 185 Hoddle St,
Richmond, VIC 3121, Australia</address>
      <phone>+61 3 9936 8032</phone>
      <fax>+61 3 9429 4683</fax>
      <email>pat.bugeja@apcrc.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Niall Corcoran</name>
      <address>5th Floor Clinical Sciences Building
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61393427000</phone>
      <fax />
      <email>niall.corcoran@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>